Clinical trials: Cutaneous Lupus
Cutaneous Lupus Erythematosus
Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE)
The primary objective of this study is to evaluate the safety and tolerability of edecesertib (formerly GS-5718) in participants with cutaneous lupus erythematosus (CLE) with or without systemic lupus erythematosus (SLE).
- Trial name
- LYNX (NCT04809623)
- Testing
- Edecesertib, Standard of Care
- Where
- 5 sites in United States
- Volunteers
- 3 people
- Sponsor
- Gilead Sciences
Central Centrifugal Scarring Alopecia, Lichen Planopilaris
Expression of Fas Protein in Skin Biopsies of Participants With Scarring Alopecia
The purpose of this research study is to see if a specific protein that we are interested in is involved in scarring hair loss. If these proteins are involved, further genetic work may also better define the disease as well as…
- Conditions
- Central Centrifugal Scarring Alopecia, Lichen Planopilaris, Discoid Lupus Erythematosus
- Trial name
- NCT00691769
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Wake Forest University
Cutaneous Lupus Erythematosus
Tapinarof for Cutaneous Lupus Erythematosus
The investigators hypothesize that topical application of Tapinarof, an FDA-approved topical Aryl hydrocarbon receptor (AHR) agonist for the treatment of plaque psoriasis, would inhibit lupus-causing T cells and lead to…
- Trial name
- NCT06661213
- Testing
- Tapinarof
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Northwestern University
Systemic Lupus Erythematosus, Cutaneous Lupus Erythematosus
A Study to Evaluate VIB7734 in Participants With Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE), Sjogren's Syndrome, Systemic Sclerosis, Polymyositis, and Dermatomyositis
The purpose of this study is to evaluate the safety and tolerability of escalating, multiple subcutaneous (SC) doses of VIB7734 in participants with Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE)…
- Conditions
- Systemic Lupus Erythematosus, Cutaneous Lupus Erythematosus, Sjogren's Syndrome, Systemic Sclerosis
- Trial name
- NCT03817424
- Testing
- VIB7734
- Where
- 30 sites in United States, Poland and 1 more
- Volunteers
- 31 people
- Sponsor
- Amgen
Lupus Nephritis
Dose Finding, Efficacy and Safety of BI 655064 in Patients With Active Lupus Nephritis
The overall purpose of the study is to assess the efficacy of three different doses of BI 655064 against placebo as add-on therapy to standard of care (SOC) treatment for active lupus nephritis in order to characterize the…
- Trial name
- NCT02770170
- Testing
- BI 655064 dose 1, BI 655064 dose 2, BI 655064 dose 3
- Where
- 74 sites in United States, Australia and 18 more
- Volunteers
- 121 people
- Sponsor
- Boehringer Ingelheim
Cutaneous Lupus Erythematosus (CLE), Systematic Lupus Erythematosus
Study of Afimetoran in Adults With Cutaneous Lupus Erythematosus
This study is evaluating whether afimetoran, an investigational oral medicine that blocks toll-like receptors 7 and 8 (TLR7/TLR8), can improve skin disease in adults with active cutaneous lupus erythematosus (CLE), with or…
- Trial name
- DISCOVERY (NCT07881120)
- Testing
- Afimetoran
- Where
- 3 sites in United States
- Volunteers
- 390 people
- Sponsor
- Beeline Medicines Corporation
Atopic Dermatitis, Healthy
Pilot Tape Harvesting Study
The main objectives of the study are: To determine if RNA recovery from tape harvesting allows for the identification of a disease gene signature (e.g., interferon [IFN] signature for lupus) or other biomarkers that may…
- Conditions
- Atopic Dermatitis, Healthy, Discoid Lupus Erythematosus, Subacute Cutaneous Lupus Erythematosus
- Trial name
- NCT02125695
- Testing
- Skin Taping, Blood Sampling, Skin Biopsy
- Where
- 2 sites in United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Biogen
Systemic Lupus Erythematosus, Lupus Nephritis
A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases
CALiPSO-1 is a Phase 1, multi-centre, dose-confirmation study to evaluate the safety and efficacy of CNTY-101 in participants with refractory B cell-mediated autoimmune diseases including those with moderate to severe systemic…
- Conditions
- Systemic Lupus Erythematosus, Lupus Nephritis, Idiopathic Inflammatory Myopathies, Diffuse Cutaneous Systemic Sclerosis
- Trial name
- CALiPSO-1 (NCT06255028)
- Testing
- CNTY-101, IL-2, Lymphodepleting Chemotherapy
- Where
- 6 sites in United States
- Volunteers
- 6 people
- Sponsor
- Century Therapeutics, Inc.
Cutaneous Lupus Erythematosus
Interdisciplinary Study Group of Lupus Erythematosus (ISGLE)
Cutaneous lupus erythematosus (CLE) is a disease with a wide spectrum of clinical manifestations and a variable prognosis. The aim of this study is to create a standardized evaluation of the different subtypes of this disease in…
- Trial name
- NCT00420173
- Testing
- Laboratory analysis
- Where
- Germany
- Volunteers
- 45 people
- Sponsor
- European Society of Cutaneous Lupus Erythematosus e.V.
Systemic Lupus Erythematosus
Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus
The purpose of this study is evaluating the efficacy and safety of SC antifrolumab in adult patients with moderate -to-severe SLE despite receiving standard therapy
- Trial name
- Tulip SC (NCT04877691)
- Testing
- Medi-546
- Where
- 140 sites in United States, Argentina and 13 more
- Volunteers
- 367 people
- Sponsor
- AstraZeneca
Discoid Lupus
A Research Study to Assess if CC-930 is Safe in Treating Subjects With Discoid Lupus Erythematosus
The purpose of the study is to assess if CC-930 is safe and tolerable in treating subjects with Discoid Lupus Erythematosus. Pharmacokinetic and pharmacodynamics will also be evaluated.
- Trial name
- NCT01466725
- Testing
- CC-930
- Where
- 19 sites in United States
- Volunteers
- 5 people
- Sponsor
- Celgene
Cutaneous Lupus, Lupus
Safety Study of AMG 557 in Subjects With Subacute Cutaneous Lupus Erythematosus
This study will be a multicenter, randomized, double-blind, placebo-controlled, multiple dose study in which approximately 24 subjects with SCLE will be enrolled.
- Trial name
- NCT01389895
- Testing
- AMG 557
- Where
- 10 sites in United States, Australia and 1 more
- Volunteers
- 1 people
- Sponsor
- Amgen
Cutaneous Lupus
Characterizing Adherence to Treatment and Satisfaction With Care in Patients With Cutaneous Lupus
This multicenter study aims to evaluate treatment adherence and satisfaction of patients with cutaneous lupus, influenced by perception of the disease, fear of side effects, cost of medications and the doctor-patient…
- Trial name
- ADlupus (NCT06506214)
- Testing
- Questionnaires
- Where
- 4 sites in France
- Volunteers
- 202 people
- Sponsor
- University Hospital, Toulouse
Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus Rash
Nicotinamide Treatment for Lupus-associated Skin Lesions in Lupus Erythematosus
This clinical study will test the efficacy and safety of nicotinamide for lupus-associated skin lesions refractory to the treatment of hydroxychloroquine plus low-dose corticosteroids in patients with cutaneous lupus…
- Trial name
- NCT03260166
- Testing
- nicotinamide
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Second Xiangya Hospital of Central South University
Discoid Lupus Erythematosus
A Pilot Trial of Topical Thalidomide for the Management of Chronic Discoid Lupus Erythematosus
The purpose of this double-masked, pilot trial is to determine whether 20 percent thalidomide ointment is safe and effective for the treatment of chronic discoid lupus erythematosus (CDLE) when used under an occlusive dressing.
- Trial name
- NCT00001680
- Testing
- Thalidomide
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
SLE (Systemic Lupus), Lupus Erythematosus, Systemic
A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
This is a single-arm, open-label, multicenter, ascending dose Phase 1 study evaluating the safety and preliminary efficacy of CTX112 in adult subjects with refractory autoimmune diseases, including active systemic lupus…
- Conditions
- SLE (Systemic Lupus), Lupus Erythematosus, Systemic, Lupus Nephritis, Systemic Sclerosis
- Trial name
- NCT06925542
- Testing
- CTX112
- Where
- 17 sites in United States, Germany and 1 more
- Volunteers
- 80 people
- Sponsor
- CRISPR Therapeutics
Cutaneous Lupus Erythematosus
Proof of Concept Study of SAR443122 in Patients With Cutaneous Lupus Erythematosus
Primary Objective: Assess the efficacy of SAR443122 in cutaneous lupus erythematosus (CLE) Secondary Objectives: Assess the effect of SAR443122 on the physician's global assessment of disease activity (PhysGA - disease activity)…
- Trial name
- CLEan (NCT04781816)
- Testing
- SAR443122
- Where
- 50 sites in United States, Argentina and 13 more
- Volunteers
- 78 people
- Sponsor
- Sanofi
Cutaneous Lupus Erythematosus
IVIg Efficacy Study to Treat Cutaneous Lupus Erythematosus
The purpose of this research study is to show that non-steroidal treatment with intravenous immunoglobulin (IVIg) can replace current systemic immunosuppressive therapy in cutaneous lupus erythematosis (CLE) patients.
- Trial name
- NCT01841619
- Testing
- IVIg
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- University of California, Irvine
Subacute Cutaneous Lupus Erythematosus
Safety and Efficacy of KRP203 in Subacute Cutaneous Lupus Erythematosus
This study will assess the safety and efficacy of KRP203 in clinically active subacute cutaneous lupus erythematosus patients, who have demonstrated inadequate response to standard treatment, such as antimalarials.
- Trial name
- NCT01294774
- Testing
- KRP203 - 1.2mg
- Where
- 8 sites in Germany, Greece and 1 more
- Volunteers
- 10 people
- Sponsor
- Novartis Pharmaceuticals
Lupus Erythematosus, Cutaneous, Lupus Erythematosus, Discoid
Cutaneous Lupus Erythematosus and Elidel
This trial evaluates the therapeutic effect of Elidel (pimecrolimus) in comparison to the corresponding vehicle in patients with chronic discoid lupus erythematosus (dLE) or subacute cutaneous lupus erythematosus (scLE).
- Trial name
- NCT00222183
- Testing
- Elidel (pimecrolimus)
- Where
- Germany
- Sponsor
- University of Leipzig